Clinical Pharmacokinetic Profile of Modafinil

@article{Robertson2003ClinicalPP,
  title={Clinical Pharmacokinetic Profile of Modafinil},
  author={Philmore Jr. Robertson and Edward T. Hellriegel},
  journal={Clinical Pharmacokinetics},
  year={2003},
  volume={42},
  pages={123-137}
}
Modafinil is a unique wake-promoting agent for oral administration. Its pharmacological properties are distinct from those of other CNS agents, and it selectively targets neuronal pathways in the sleep/wake centres of the brain.After single or multiple oral doses, modafinil is readily absorbed, reaching maximum plasma concentrations at 2–4 hours after administration and pharmacokinetic steady state within 2–4 days. Its pharmacokinetics are dose-independent between 200 and 600 mg/day. The… 
Population Pharmacokinetics of Modafinil and Its Acid and Sulfone Metabolites in Chinese Males
TLDR
A robust population pharmacokinetic model for modafinil and its metabolites was developed for the first time and based on this model, individualized dosing based on weight is now possible.
Comparison of Steady-State Plasma Concentrations of Armodafinil and Modafinil Late in the Day Following Morning Administration
TLDR
At steady state, armodaf inil produces consistently higher plasma drug concentrations late in the day than modafinil when compared on a milligram- to-milligram basis following once-daily administration.
Population Pharmacokinetic Modeling of Armodafinil and Its Major Metabolites
TLDR
These population pharmacokinetic models were from the largest population of adults reported to date and provide a robust characterization of the pharmacokinetics of armodaf inil, R‐modafinil acid, and modafinIL sulfone in adults.
Armodafinil and Modafinil Have Substantially Different Pharmacokinetic Profiles Despite Having the Same Terminal Half-Lives
TLDR
The different pharmacokinetic profile of armodafinil may result in improved wakefulness throughout the day in patients with excessive sleepiness associated with treated obstructive sleep apnoea, shift work disorder or narcolepsy.
The Effect of Modafinil on the Safety and Pharmacokinetics of Lorlatinib: A Phase I Study in Healthy Participants
TLDR
Lorlatinib 100 mg may be safely co-administered with moderate CYP3A inducers, and single doses of lorLatinib 50–100 mg were well tolerated when administered alone and in the presence of steady-state modafinil.
Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects
TLDR
Modafinil is a nonamphetamine nootropic drug with an increasingly therapeutic interest due to its different sites of action and behavioral effects in comparison to cocaine or amphetamine, and its psychotropic and cognitive effects are also attractive in several other pathologies and conditions that affect sleep structure, induce fatigue and lethargy, and impair cognitive abilities.
Psychotropic drugs and renal failure: Translating the evidence for clinical practice
TLDR
The adjudication of safe and effective doses for any psychotropic agent needs to be individualized, including dosage adjustment, slow titration, and careful monitoring for serious adverse events should be incorporated into practice.
Bioequivalence of Two Oral Formulations of Modafinil Tablets in HealthyMale Subjects under Fed and Fasting Conditions
TLDR
The results of this bioequivalence study showed the equivalence of the two studied products in terms of the rate of absorption and the extent of absorption as indicated by Cmax and AUC0-t and A UC0- ∞.
Modafinil: Development and Use of the Compound
TLDR
A longer-acting form of modafinil, armodaf inil, the R-enantiomer, was approved for the treatment of excessive daytime sleepiness associated with narcolepsy contributing to a refinement of the Treatment of nar colepsy.
Pharmacokinetic Changes of Psychotropic Drugs in Patients with Liver Disease
TLDR
Kinetic studies for centrally acting drugs with predominant hepatic metabolism should be carried out in patients with liver disease to allow precise dose recommendations for enhanced patient safety, if information from clinical studies is lacking.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 34 REFERENCES
Steady‐State Pharmacokinetics and Tolerability of Modafinil Administered Alone or in Combination with Dextroamphetamine in Healthy Volunteers
TLDR
The results indicate that administration of low‐dose dextroamphetamine in this dosing regimen does not alter the steady‐state pharmacokinetics of modafinil, and the combination has a similar tolerability profile as modaf inil alone.
Effect of Modafinil at Steady State on the Single‐Dose Pharmacokinetic Profile of Warfarin in Healthy Volunteers
TLDR
The results indicate that the marked suppression of CYP2C9 activity in vitro does not translate into a similar effect clinically, however, limitations arising from investigation of single doses of warfarin preclude global conclusions about the potential for more subtle interactions after chronic Warfarin administration.
Steady‐State Pharmacokinetics and Tolerability of Modafinil Given Alone or in Combination with Methylphenidate in Healthy Volunteers
TLDR
The results indicate that administration of low‐dose methylphenidate 8 hours after treatment with modafinil does not appearto alter the steady‐state pharmacokinetics of modafInil in healthy volunteers.
Single‐Dose Pharmacokinetics of Modafinil and Methylphenidate Given Alone or in Combination in Healthy Male Volunteers
TLDR
Coadministration of modafinil and methylphenidate did not significantly alter the pharmacokinetics of d‐ or l‐threo‐methylphenidate, except for a small decrease in Vd/F of l‐thano‐ethylphenidate.
Comparison of the Single‐Dose Pharmacokinetics and Tolerability of Modafinil and Dextroamphetamine Administered Alone or in Combination in Healthy Male Volunteers
TLDR
The data collected in this study of 24 healthy volunteers suggest that concomitant administration of single oral doses of modafinil and dextroamphetamine has no clinically significant effects on the pharmacokinetic profile of either agent.
Modafinil binds to the dopamine uptake carrier site with low affinity.
TLDR
The results suggest a nonadrenergic mode of action in modafinil, and experiments in narcoleptic canines have shown that the compound does not modify canine cataplexy even at doses promoting alertness.
Open‐Label, Single‐Dose Pharmacokinetic Study of Modafinil Tablets: Influence of Age and Gender in Normal Subjects
TLDR
Results from this study indicated that there were age and gender effects on modafinil clearance processes, and the clearance rate in males decreased with age while young females cleared modaf inil at a faster rate than young males.
Hepatic Drug Metabolism and Aging
TLDR
Although there is considerable variation in the effect of age on drug biotransformation, the metabolism of many drugs is impaired in the elderly, and initial doses of metabolised drugs should be reduced in older patients and then modified according to the clinical response.
Modafinil : A Review of its Pharmacology and Clinical Efficacy in the Management of Narcolepsy.
TLDR
Preliminary findings indicate that, unlike other psychostimulants, the drug is unlikely to be abused and is not associated with withdrawal phenomena, therefore, modafinil is likely to be an effective therapeutic option for the treatment of EDS in patients with narcolepsy.
Interaction of modafinil and clomipramine as comedication in a narcoleptic patient.
TLDR
A narcoleptic patient chronically treated with clomipramine who started receiving modafinil showed a significant dose-dependent and reversible increase under modaf inil, and the authors attribute the relevant pharmacokinetic interaction to another clomIPramine-metabolizing enzyme.
...
1
2
3
4
...